Skip to main content
Study shows SGLT2 inhibitors' renoprotective effect in diabetes
10/11/2019

A study of 38,723 people with type 2 diabetes found the SGLT2 inhibitors canagliflozin, dapagliflozin and empagliflozin were associated with reduced risk for kidney disease-related mortality, dialysis or transplantation. The findings, published in The Lancet Diabetes & Endocrinology, showed that SGLT2 inhibitor use was also associated with reduced risk for acute kidney injury and end-stage kidney disease.

Full Story: